Study S001231

Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07574723
Acronym: TiTRE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 68
Start: 2026-05-15
Primary completion: 2029-05-15
Lead sponsor: Dasman Diabetes Institute
Conditions: Obesity
Interventions: DRUG:Tirzepatide (Per-label titration); DRUG:Tirzepatide (Flexible titration)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR) [From enrollment (at baseline) to the end of treatment at 76 weeks.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.